Pancreatic ductal adenocarcinoma (PDAC) is the most common histologic subtype of pancreatic cancer, arising from ductal epithelium and associated with poor prognosis.
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
Daraxonrasib reduced death risk by 60% versus chemo in Phase 3 pancreatic cancer trial (median OS 13.2 vs 6.7 months). EMA began rolling review; zoldonrasib combo data presented at ESMO GI.
PancreaSure detected advanced PDAC with 87.9% sensitivity and 97.7% specificity, outperforming CA19-9 alone. PanMETAI, an AI metabolomics model, achieved AUC 0.99 in training and 0.93 in external validation for early PDAC detection.
PanTher Therapeutics completed dose escalation in its Phase 1b trial of PTM-101 for pancreatic cancer, identifying 400mg as the recommended Phase 2 dose. Other pancreatic cancer updates include ASCO 2026 RASolute 302 data, a Nature study on NDRG1, and a giant acinar cell carcinoma case report.
Two studies characterize cancer-associated fibroblast (CAF) heterogeneity. One finds distinct collagen biomarker responses to profibrotic stimuli, and another introduces DeCAF, a single-sample classifier that predicts CAF subtypes and immunotherapy response in pancreatic cancer.
Research highlights ferroptosis for overcoming drug resistance in digestive cancers. A study of Fuzheng Pill identified 236 components and showed it promotes apoptosis via the mitochondrial pathway.
Incyte has started the phase 3 Dawn-03 trial of INCB161734 plus chemotherapy in first-line KRAS G12D-mutant pancreatic cancer. The move comes while the phase 1 study remains halted in four European countries after pneumonitis cases, including one grade 5 event.
Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
A new four-marker blood test detects pancreatic cancer with 91.9% accuracy across all stages and 87.5% accuracy for early-stage disease. The test combines two newly identified proteins with existing biomarkers and can differentiate cancer from non-cancerous conditions. While promising for pancreatic cancer, most cancers still cannot be reliably diagnosed with blood tests alone.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07769502 |
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers |
NOT_YET_RECRUITING | PHASE2 |
| NCT07745790 |
Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07678593 |
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07629960 |
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations |
RECRUITING | PHASE1/PHASE2 |
| NCT07623642 |
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07589205 |
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT07562152 |
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE3 |
| NCT07483554 |
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors |
RECRUITING | PHASE2 |
| NCT07432633 |
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications |
RECRUITING | PHASE1/PHASE2 |
| NCT07328607 |
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy |
RECRUITING | NA |
